COVID-19 vaccines are considered promising agents in the control of the pandemic. Although their safety was assessed in randomised clinical trials, severe adverse events (AEs) have been reported after large-scale administration. This study aims to evaluate thromboembolic AEs reported after vaccination in a real-world context and how they led to the interruption of vaccination campaigns. We also review the benef...
Since early 2020, the world’s attention has shifted to the COVID-19 pandemic, and the medical and scientific community has joined forces to fight it. However, although necessary, this diversion of attention has had an impact in all areas of health. The effect of COVID-19 on tuberculosis services is estimated to be global and dramatic. All over the world, we witnessed the reallocation of health care workers to f...
In late December 2019, global attention shifted to China after several local health facilities reported clusters of patients with pneumonia of unknown origin epidemiologically linked to the Huanan Seafood Wholesale Market in the municipality of Wuhan, one of the country’s central cities. Local health authorities identified a novel betacoronavirus, provisionally called 2019-nCoV, the third zoonotic coronavirus i...
Early introduction of appropriate antibiotherapy is one of the major prognostic-modifying factors in community acquired pneumonia (CAP). Despite established guidelines for empirical therapy, several factors may influence etiology and, consequently, antibiotic choices. The aims of this study were to analyze the etiology of CAP in adults admitted to a northern Portugal University Hospital and evaluate the yield o...
BACKGROUND: Skeletal-related events (SREs) occur frequently in patients with bone metastases as a result of breast (BC) and prostate (PC) cancers. They increase both morbidity and mortality and lead to extensive health-care resource utilization. METHODS: Health care resource utilization by BC/PC patients with at least one SRE during the preceding 12 months was assessed through retrospective chart review. SRE-tr...
The efficacy and safety of docetaxel were evaluated in an open, multicentric, non comparative study involving 24 patients with locally advanced or metastatic breast cancer, eligible for second line or subsequent anticancer chemotherapy; the results confirm a global response around 50%, suggesting some advantages when compared to the usual treatments in this set of patients; the median duration of response, the ...